Qasem Farah, Abu-Qamar A'sem, Aqel Batool, Aladayleh Rand, Ilham Alteerah R, Magableh Ahmad, Bawa Neh Hisham, Al-Fararjeh Feras, Awidi Abdalla
Medical school, The University of Jordan, Amman, Jordan.
Al-Basheer Hospital, Ministry of Health, Amman, Jordan.
Mediterr J Hematol Infect Dis. 2022 May 1;14(1):e2022031. doi: 10.4084/MJHID.2022.031. eCollection 2022.
Scanty reports from the middle east and north Africa (MENA) region have been published on multiple myeloma (MM). Multiple myeloma registry has been established at Jordan University Hospital (JUH) since 2009. Our work aims to review this Multiple Myeloma registry with data from 113 patients diagnosed with MM at JUH and analyze their management and course.
This is a non-interventional and retrospective analysis of the MM registry from 2009-to 2016 involving 113 patients at JUH. Statistical analysis was done using the Statistical Package for the Social Sciences (SPSS). Overall survival (OS) was analyzed with the Kaplan-Meier method. P-value was considered significant if it was (<0.05).
We found no gender difference in this registry. The median age is 62 years. Most patients are in ISS stage II and III (36.28% for each). Immunoglobulin type G Kappa is the dominant subtype. Bone pain is the most common presenting symptom. The most common laboratory finding is anemia (45.6%). Most of our patients (85.2%) had received thalidomide and dexamethasone, while only 14.8% received bortezomib, thalidomide, and dexamethasone. Our patients' mean overall survival (OS) was 74 months, and the median survival was 38 months. For ISS stages I, II, and III, median OS was 96, 46, and 16 months.
MM in a developing country presents a challenging disease compared to industrial countries in both epidemiology and management. An improved road map in the care of MM in these countries is needed. The use of three or four drugs combination upfront is warranted. However, this is limited because of the high cost of these drugs. We expect the following decade to show better survival and quality of life for MM patients once these drugs are widely used.
中东和北非（MENA）地区关于多发性骨髓瘤（MM）的报道较少。自2009年起，约旦大学医院（JUH）建立了多发性骨髓瘤登记处。我们的工作旨在回顾该多发性骨髓瘤登记处中JUH诊断的113例MM患者的数据，并分析他们的治疗及病程。
这是一项对2009年至2016年JUH的MM登记处进行的非干预性回顾性分析，涉及113例患者。使用社会科学统计软件包（SPSS）进行统计分析。采用Kaplan-Meier法分析总生存期（OS）。P值<0.05被认为具有统计学意义。
我们发现该登记处中无性别差异。中位年龄为62岁。大多数患者处于国际分期系统（ISS）II期和III期（各占36.28%）。免疫球蛋白G κ型是主要亚型。骨痛是最常见的首发症状。最常见的实验室检查结果是贫血（45.6%）。我们的大多数患者（85.2%）接受了沙利度胺和地塞米松治疗，而只有14.8%的患者接受了硼替佐米、沙利度胺和地塞米松治疗。我们患者的平均总生存期（OS）为74个月，中位生存期为38个月。对于ISS I期、II期和III期，中位OS分别为96个月、46个月和16个月。
与工业化国家相比，发展中国家的MM在流行病学和治疗方面都是一种具有挑战性的疾病。这些国家需要改进MM的治疗路线图。前期使用三种或四种药物联合治疗是有必要的。然而，由于这些药物成本高昂，这受到了限制。我们预计，一旦这些药物广泛应用，未来十年MM患者的生存期和生活质量将会改善。
